SEOUL, November 17 (AJP) - Lotte Biologics has signed a contract manufacturing deal with a global pharmaceutical company, its first large-scale commercial production order, the company said Tuesday.
It did not name the client and kept the product, contract value and location confidential under the deal’s terms.
The order lands before the company’s first plant in Songdo, Incheon, is finished. The 120,000-liter facility has eight 15,000-liter stainless steel bioreactors and is set to begin full operations next year.
“Unlike the industry practice of ramping up orders after a plant is completed, we brought in a major client at the design and construction stage, securing a stable revenue base,” a company official said.
Lotte Biologics plans to combine its commercial manufacturing experience at its Syracuse campus in the United States with Songdo’s capacity to grow its contract development and manufacturing business.
Tags: Lotte Biologics, Syracuse, United States, Bioreactors, Songdo, Incheon, Pharama, CDMO, Samsung Biologics
It did not name the client and kept the product, contract value and location confidential under the deal’s terms.
The order lands before the company’s first plant in Songdo, Incheon, is finished. The 120,000-liter facility has eight 15,000-liter stainless steel bioreactors and is set to begin full operations next year.
“Unlike the industry practice of ramping up orders after a plant is completed, we brought in a major client at the design and construction stage, securing a stable revenue base,” a company official said.
Lotte Biologics plans to combine its commercial manufacturing experience at its Syracuse campus in the United States with Songdo’s capacity to grow its contract development and manufacturing business.
Tags: Lotte Biologics, Syracuse, United States, Bioreactors, Songdo, Incheon, Pharama, CDMO, Samsung Biologics
Copyright ⓒ Aju Press All rights reserved.